Table 1

Baseline characteristics of included patients

ParameterPatients with RA (N=330)
Female gender, n (%)224 (67.9)
Age (years), mean (SD)62.0 (11.6)
Disease duration, mean (SD)11.2 (9.6)
DAS28-ESR,* mean (SD)3.3 (1.4)
SJC (0–28), mean (SD)2.3 (3.5)
TJC (0–28), mean (SD)4.1 (5.5)
ESR (mm/hour), mean (SD)18.7 (17.6)
RAPID3 total score (0–10),‡§ mean (SD)3.8 (2.1)
RAPID3 function (0–10), mean (SD)2.5 (1.9)
RAPID3 VAS pain (0–10), mean (SD)4.3 (2.6)
RAPID3 PGA (0–10), mean (SD)4.7 (2.4)
Treatment status
 bDMARD only, n(%)155 (47)
 MTX only, n (%)77 (23.3)
 bDMARD plus MTX, n (%)71 (21.5)
 No bDMARD**/MTX, n (%)27 (8.2)
  • *DAS28-ESR (four variables, ESR-based).

  • †N=213.

  • ‡RAPID3 (functioning, VAS pain and PGA).

  • §RAPID3 0–30 was converted to a 0–10 scale; high numbers reflect bad scores.

  • ¶bDMARD includes TNFi (81.9%; etanercept, infliximab, adalimumab, certolizumab–pegol and golimumab) and no TNFi (18.1%; rituximab, abatacept and tocilizumab).

  • **Patients (n=27) neither on bDMARDs nor on MTX were treated with leflunomide, sulfasalazine or hydroxychloroquine.

  • bDMARD, biological disease-modifying antirheumatic drug; DAS28-ESR, Disease Activity Score in 28 joints that includes the erythrocyte sedimentation rate; ESR, erythrocyte sedimentation rate; MTX, methotrexate; PGA, patient global assessment; RA, rheumatoid arthritis; RAPID3, Routine Assessment of Patient Index Data 3; SJC, swollen joint count; TJC, tender joint count; TNFi, tumor necrosis factor inhibitor; VAS, Visual Analogue Scale.